Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ephedra Bill Likely To Be Subject Of Hearing Within The Next Month

This article was originally published in The Tan Sheet

Executive Summary

A hearing on the "Ephedra Public Protection Act" (HR 1075), which would ban the sale of all ephedrine alkaloid-containing dietary supplements under certain conditions, is expected within the next month
Advertisement

Related Content

Supplement Bill Increasing FDA Access To Safety Data Planned By Waxman
Supplement Bill Increasing FDA Access To Safety Data Planned By Waxman
Supplement Bill Increasing FDA Access To Safety Data Planned By Waxman
Congressional DSHEA Amendment Potential Prompts NNFA Lobbying Activity
Congressional DSHEA Amendment Potential Prompts NNFA Lobbying Activity
Congressional DSHEA Amendment Potential Prompts NNFA Lobbying Activity

Topics

Advertisement
UsernamePublicRestriction

Register

PS095215

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel